Lv11
20 积分 2026-07-23 加入
Postmarket review of photosensitivity associated with select BRAF and MEK inhibitors
5小时前
已完结
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
21天前
已完结
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
21天前
已完结
The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols
21天前
已完结
Germline CDK12 variants in aggressive prostate cancer
23天前
已完结
CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement
23天前
已完结
Dose-finding and optimization in drug development for rare diseases
1个月前
已完结
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
1个月前
已完结
Biosimilars approved for hematology use: lessons from comparative efficacy studies and comparative analytical assessments
1个月前
已完结
Four Decades of History & Evolution of Clinical Pharmacology at US Food and Drug Administration (FDA)—Part II: Dose Individualization and Approvability Evidence
1个月前
已完结
皖公网安备34019202002308
